Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the sequencing of BCMA-targeting CAR-T cells and bispecific antibodies in relapsed/refractory (R/R) multiple myeloma, commenting on the role of BCMA loss, and referencing data from recent clinical trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.